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Chronic kidney disease (CKD) is a prognostic factor in heart failure (HF) and is associated with an increased 
mortality risk and increased risk for admission. Furthermore, 
worsening of renal function during admission and treatment is 
described in 15% to 20% of patients with HF and is associated 
with a poor outcome.1–3
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Research on renal dysfunction in HF has focused on risk strat-
ification4,5 and identification of new renal biomarkers.6 Little 
research has focused on pathogenesis of renal dysfunction in 
HF, despite the fact that approximately half of patients with HF 
are in CKD stage III to V.7,8 From post hoc analyses of random-
ized clinical trials, it is well known that angiotensin-converting 
enzyme-inhibitors (ACE-I) and aldosterone receptor antago-
nists (ARA) increase plasma creatinine concentration, yet still 
improve survival.9–11 However, the risk of developing end-stage 
renal disease (ESRD) requiring dialysis in patients with HF 
treated with neurohormonal blockade is unknown.12 In light of 
the renal side effects of HF therapy, and the prolonged survival 
in systolic HF, ESRD might be an increasing problem in clini-
cal practice.13,14 Conversely, it may be speculated that renin–
angiotensin–aldosterone system blockade has a reno-protective 
effect over time, in turn reducing the need for renal replace-
ment therapy. Finally, potential predictors of development of 
ESRD in systolic HF have not been identified.
Using data from a large cohort followed in The Danish 
Heart Failure Clinics Network from 2002 to 2009, the aim 
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Background—Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction 
progresses to end-stage renal disease (ESRD) is unknown. Therefore, we examined incidence and predictors of ESRD in 
outpatients with HF.
Methods and Results—Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD 
from the Danish Registry on Dialysis. Renal function was estimated by The Chronic Kidney Disease Epidemiology 
Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)—group I: ≥60 mL/min per 
1.73 m2, group II: 30 to 59 mL/min per 1.73 m2, group III: 15 to 29 mL/min per 1.73 m2, group IV: <15 mL/min per 1.73 
m2. Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed 
and predictors of ESRD identified. A total of 8204 patients were included in the analyses. Median age was 70 years (Q, 
61–77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24–40), and median eGFR was 68 
(Q, 51–85) mL/min per 1.73 m2. Forty-one patients developed ESRD (1.3/1000 patient-years). Baseline eGFR group 
II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of 
diuretics, and age <60 years (P=0.016) were associated with time to ESRD.
Conclusions—ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/
min per 1.73 m2. A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an 
increased risk for ESRD.  (Circ Heart Fail. 2013;6:1124-1131.)
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of the present study was to identify predictors and describe 
the incidence of ESRD in outpatients with systolic HF treated 
according to guideline therapy.
Methods
Registry Data Sources: Study Population, End 
Points, and Pharmacological Treatment
Study Population
Information about clinical characteristics was obtained from the 
electronic patient file and research database, Hjerterplus.15 It was col-
lected from 26 Danish HF clinics, all members of the Danish Heart 
Failure Clinics Network (DHFCN) between 2002 and 2009, which 
comprises approximately half of all Danish patients with HF. Patients 
were referred to the clinics, when diagnosed with systolic HF (left 
ventricular ejection fraction [LVEF] <45% by echocardiography) for 
education and uptitration of HF guideline therapy. Patients with HF 
and preserved LVEF are not referred to the HF clinics in Denmark 
systematically and were, therefore, excluded. The inclusion ended on 
December 31, 2009.
End Points: ESRD and Mortality
Information of onset of ESRD, defined as initiation of long-term di-
alysis, was obtained from the Danish National Registry on Dialysis 
and Transplantation (NRDT) from 2002 to 2010.16 This registry con-
tains information on all patients starting long-term hemo- or perito-
neal dialysis, defined as a need for therapy of ≥90 days and has been 
validated and found complete.16 Primary renal diagnosis, registered 
as cause for ESRD, was also retrieved from NRDT. Patients with 
ESRD before referral to a HF clinic were excluded. The end point of 
death was obtained from the Central Population Registry, in which all 
deaths are registered within 2 weeks. Immigration is also registered, 
but no patients in the present cohort immigrated.
The study was approved by the Danish Data Protection Agency 
and the review board of the DHFCN and the NRDT. Approval by an 
ethics committee and written informed consent are not required for 
retrospective registry studies in Denmark.
Pharmacological Treatment
Information on medical products prescribed to and bought by each 
patient was obtained from The Danish Registry of Medicinal Products 
Statistics, which keeps records of all drug prescriptions dispensed 
from Danish pharmacies since 1995.17 Prescriptions dispensed from 
pharmacies 90 days after the baseline visit were used for analyses. We 
included the use of ACE-I or angiotensin receptor blockers (ARB), 
β-blockers, ARA, acetylsalicylic acid, statins, and diuretics. The use 
of diuretics was defined as an average daily dose of >80 mg of furoso-
mide (or equivalent), as some patients did not have a daily intake but 
used diuretics for self-administration when symptomatic.
Patients were linked between the databases by their unique per-
sonal registry number, provided to all Danish citizens at birth or at 
achievement of permanent residency status in Denmark.
Renal Function
Renal function was estimated by the Chronic Kidney Disease 
Epidemiology Collaboration equation, incorporating age, race, sex, 
and plasma creatinine concentration.18 Patients were then divided 
into 4 estimated glomerular filtration rate (eGFR) groups—group I: 
≥60 mL/min per 1.73 m2, group II: 30 to 59 mL/min per 1.73 m2, 
group III: 15 to 29 mL/min per 1.73 m2, and group IV: <15 mL/min 
per 1.73 m2. Intervals for eGFR groups were chosen so they matched 
CKD stages as specified by the National Kidney Disease Foundation 
Outcomes Quality Initiative Guidelines.19 Patients without CKD and 
CKD stage I+II were placed in eGFR group I, as we did not have in-
formation on albuminuria and could not distinguish between patients 
without renal disease and patients with mild renal disease defined as 
an eGFR >90 mL/min per 1.73 m2 and albuminuria. The patients with 
an eGFR from 60 to 89 mL/min per 1.73 m2 were also included in 
eGFR group I, as they could have decreased renal function according 
to age or experience mild renal disease.
Statistics
Baseline patient’s characteristics in the eGFR groups were compared 
by χ2 tests for discrete variables, and by 1-way ANOVA for paramet-
ric and trend tests, general linear models, for continuous variables.
Patients registered without information about plasma creatinine 
concentration were excluded. Baseline variables for included and 
excluded patients were compared with evaluate selection bias. 
Crude rates for death and for ESRD were calculated separately 
in each group as number of events per 1000 person-years of HF 
(/1000 patient-years), each patient contributed with time calculated 
in days, from the baseline visit in the HF clinic to an event (=death 
or initiation of renal replacement therapy) or censoring (=death or 
end of study).
Because of the competing risk of death to ESRD, end points were 
evaluated by cumulative incidence functions according to baseline 
eGFR group and not by Kaplan–Meier estimates and log-rank test.20 
Time-dependent multivariate Cox proportional hazard models were 
constructed for ESRD, for death and for the composite end point of 
ESRD or death, adjusted for the clinical relevant explanatory vari-
ables chosen from the baseline data: eGFR, sex, age, hypertension, 
diabetes mellitus, New York Heart Association (NYHA) class, LVEF, 
use of ACE/ARB, β-blockers, ARA, acetylsalicylic acid, statin, and 
diuretics. Because of the number of end points in the model includ-
ing time to ESRD as end point, we created a basic model (model 0) 
including age, sex, renal function, and uncontrolled hypertension and 
added in separate model covariates of specific interest: diabetes mel-
litus, ACE/ARB, and diuretics (model Ia-c).
Model assumptions, the proportional hazards, linearity of continu-
ous variables, and lack of interactions were tested and found valid 
unless otherwise specified. Because of large differences in the inci-
dence of ESRD between the eGFR groups, we chose to repeat the 
multivariate Cox models for ESRD stratified by eGFR groups to ap-
proach whether there were any differences in significant predictors. A 
P value <0.05 (2-sided) was considered significant.
Results
Study Population
A total of 10 458 patients were registered with a baseline 
visit in the HF clinics during the period of 7 years (Figure 1). 
Two-thousand thirty-nine (n=2239) did not have a plasma 
creatinine concentration registered and 38 patients had ESRD 
before onset of systolic HF. These patients were excluded. Fif-
teen (n=15) patients excluded because of missing creatinine, 
developed ESRD (Table 1; Figure 1).
In total, 8204 patients with complete data were included 
in the final analyses. Median follow-up was 3.7 (quartiles 
[Q], 2.4–5.1) years. During this period 41 patients devel-
oped ESRD (1.3/1000 patient-years), and 2652 patients died 
(84/1000 patient-years; Table 2). All 41 patients with ESRD 
were registered with start of dialysis, no patients were regis-
tered as recipients of a renal transplant.
Patient characteristics are presented in Table 1 for the 
entire cohort and according to eGFR groups. Median age 
was 70 (Q, 61–77) years, 28% were women, median LVEF 
30 (Q, 24–40) %, and median eGFR was 68 (Q, 51–85) mL/
min per 1.73 m2. Patients with poorer renal function were 
older, had a higher NYHA class, more frequently had diabe-
tes mellitus, and had a lower LVEF. Increasing eGFR group 
was associated with declining use of ACE-I/ARBs, ARAs, 
and β-blockers while more patients were treated with ace-
tylsalicylic acid. Frequency of uncontrolled hypertension did 
 by guest on February 6, 2017
http://circheartfailure.ahajournals.org/
D
ow
nloaded from
 
1126  Circ Heart Fail  November 2013
not differ between groups. Patients in eGFR group IV were 
younger than patients in eGFR group III, had a lower LVEF, 
and fewer had diabetes mellitus.
Incidence of ESRD and Mortality
Of the 25 patients in eGFR group IV at baseline, 5 devel-
oped ESRD, resulting in an incident ESRD rate of 106/1000 
patient-years, and 18 died leaving the crude mortality rate 
at 340/1000 patient-years. In eGFR group III, 22 patients of 
372 progressed to ESRD and 246 died. Crude ESRD rate was 
23.0/1000 patient-years and crude mortality rate 244/1000 
patient-years. In eGFR group II, 11 patients of 2695 progressed 
to ESRD and 1223 died, resulting in an incident ESRD rate of 
1.2/1000 patient-years and crude mortality rate of 129/1000 
patient-years. In the last eGFR group, 3 developed ESRD and 
1165 died, resulting in an incident ESRD rate of 0.10/1000 
patient-years and a crude mortality rate of 55.4/1000 patient-
years (Table 3; Figure 2).
Mortality and Cumulative Incidence of ESRD
The cumulative incidence functions for ESRD and death 
showed that eGFR groups were associated with both end points, 
but death occurred much more frequently and the difference in 
scale on the y-axis should be noted (Figure 3A and 3B).
Cox Multivariate Proportional Hazard  
Model: ESRD
In model 0, eGFR group at the baseline was closely associated 
with time to ESRD. For eGFR group II, a hazard ratio (HR) of 
13.39 (95% confidence interval [CI], 3.2–48.6; P=0.001); for 
eGFR group III, a HR of 322.1 (95% CI, 93.3–1122; P<0.001), 
and for eGFR group IV, a HR of 1586 (95% CI, 365.3–6889; 
P<0.001) reflect the natural link between decreased renal 
function and ESRD. Age <60 years (HR, 3.07; 95% CI, 1.24–
7.63; P=0.016) and uncontrolled hypertension, that is, systolic 
arterial blood pressure >140 mm Hg at the baseline visit (HR, 
1.9; 95% CI, 1.00–3.59; P=0.049), were also associated with 
time to ESRD, whereas age 60 to 69 years (HR, 2.89; 95% 
CI, 1.36–6.16; P=0.057) was not. In model I, diabetes mel-
litus (HR, 1.87; 95% CI, 0.96–3.72; P=0.072) and ACE/ARB 
(HR, 0.54; 95% CI, 0.28–1.03; P=0.061) were not associated 
with time to ESRD, but need for diuretics was (HR, 1.39; 95% 
CI, 0.90–1.65; P=0.023). All results are presented in Table 2 
(model 0+Ia-c).
Five patients (n=5) almost fulfilled the criteria for dialysis 
at their baseline visit to the HF clinic. This may have weighted 
our results in favor of the observed close association between 
eGFR group and ESRD in the whole cohort. Therefore, we 
performed analyses stratified by eGFR groups, to identify 
patients with preserved kidney function but at risk. It was not 
possible to identify any association between the clinical vari-
ables and ESRD either in eGFR group I, because of the low 
number of events (n=3), or in eGFR group IV, because of the 
low number of patients (n=25). In eGFR groups II and III, 
we identified age <70 years and uncontrolled hypertension as 
risk markers for ESRD. Surprisingly, diabetes mellitus was 
not a risk marker for ESRD in these subgroups (Table I in the 
online-only Data Supplement).
Danish Heart Failure Clinics Database “Hjerterplus”  
(2002-2009) N=10,458 
National Prescriptions Database 
(Baseline +90 days) N=8,219 
ESRD before Heart Failure
N=15
Danish National Database on Dialysis and Transplantation
(2002-dec 2011) N= 8,219
Missing creatinine
N= 2,239
Central Population Registry (vital status)  
(Dec 2011) N=8,204
eGFR group II
N=2,695
eGFR group III
N=372
eGFR group IV
N=25
eGFR group I
N=5,112
Study population
(Dec 2011) N=8,204
Figure 1. Study population and register flow chart. Study population consisted of patients in Hjerterplus. The Danish Heart Failure Net-
works Clinics database and information on prescribed medication, end-stage renal disease (ESRD), vital status were added from relevant 
national registries. The registers were merged and each patient was identified by his/hers unique central personal registry number. eGFR 
indicates estimated glomerular filtration rate.
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Cox Multivariate Proportional Hazard  
Model: Mortality 
A total of 2652 patients died (84/1000 patient-years). Age >80 
years (HR, 1.67; 95% CI, 1.52–2.83; P<0.001), eGFR group 
II (HR, 1.37; 95% CI, 1.26–1.50; P<0.001), eGFR group III 
(HR, 1.83; 95% CI, 1.57–2.12; P<0.001), eGFR group IV 
(HR, 2.75; 95% CI, 1.72–4.42; P<0.001), diabetes mellitus 
(HR, 1.18; 95% CI, 1.07–1.32; P=0.002), LVEF <30% (HR, 
1.24; 95% CI, 1.15–1.34; P<0.001), NYHA class III+IV 
(HR, 1.32; 95% CI, 1.22–1.44; P<0.001), and use of diuretics 
>80 mg of furosomide, or equivalent, on an averagely daily 
dose (HR, 1.25; 95% CI, 1.19–1.30; P<0.001) were all sig-
nificantly associated with increased risk of death. Age <60 
years (HR, 0.35; 95% CI, 0.29–0.50; P<0.001), age 60 to 69 
years (HR, 0.62; 95% CI, 0.55–0.69; P<0.001), uncontrolled 
hypertension (HR, 0.81; 95% CI, 0.73–0.89; P<0.001), and 
use of ACE-I/ARB (HR, 0.54; 95% CI, 0.49–0.59; P<0.001), 
β-blocker (HR, 0.54; 95% CI, 0.49–0.57; P<0.001), statin 
(HR, 0.75; 95% CI, 0.69–0.81; P<0.001), and acetylsalicylic 
acid (HR, 0.79; 95% CI, 0.73–0.85; P<0.001) were all associ-
ated with a decreased mortality risk (Table 2, model II).
Cox Multivariate Proportional Hazard Model: 
Composite End Point, ESRD, and Death
eGFR group II (HR, 1.39; 95% CI, 1.28–1.52; P<0.001), eGFR 
group III (HR, 1.98; 95% CI, 1.71–2.31; P<0.001), eGFR 
group IV (HR, 3.36; 95% CI, 2.12–5.34; P<0.001), NYHA 
class III+IV (HR, 1.32; 95% CI, 1.22–1.44; P<0.001), dia-
betes mellitus (HR, 1.19; 95% CI, 1.11–1.32; P=0.002), and 
age ≥80 years (HR, 1.64; 95% CI, 1.40–1.80; P<0.001) were 
all associated with time to death or ESRD. Younger age, <60 
years (HR, 0.35; 95% CI, 0.30–0.40; P<0.001), 60 to 69 years 
(HR, 0.63; 95% CI, 0.57–0.70; P<0.001), and uncontrolled 
hypertension (HR, 0.82; 95% CI, 0.74–0.91; P<0.001), use 
of an ACE-I/ARB (HR, 0.54; 95% CI, 0.49–0.59; P<0.001), 
β-blocker (HR, 0.53, 95% CI, 0.49–0.58; P<0.001), and statins 
(HR, 0.75; 95% CI, 0.69–0.82; P<0.001) were associated with 
a decreased risk of death or ESRD (Table 2, model III).
Missing Data Analyses
The included (n=8204) and excluded (n=2239) patients were 
similar with respect to important clinical variables (missing ver-
sus included): female gender (29% versus 28%; P=0.434), age 
(69.8 years versus 70.0 years; P=0.418), and diabetes mellitus 
(14.8% versus 14.6%; P=0.771). We observed that excluded 
patients were less symptomatic (NYHA class I+II; 87.5% versus 
77.4%; P<0.001), but more had LVEF <30% (56% versus 67%; 
P<0.001). At baseline patients with missing creatinine were 
treated less frequently with guideline-based therapy. Mortality 
and ESRD rates did not differ between groups (Table II in the 
online-only Data Supplement). Age, sex, and incidence rates of 
death and ESRD did not differ between groups, and the low inci-
dence of ESRD seems not to be explained by selection bias at 
enrollment because of missing registration of plasma creatinine.
Renal Diagnosis
The most common diagnosis registered as cause of ESRD was 
CKD of unknown pathogenesis (34%), the main part (32%) 
Table 1. Patient Characteristics
eGFR Groups All eGFR I eGFR II eGFR III eGFR IV P Value
N 8204 5112 2695 372 25
Age, y 70 (46–86) 65 (44–82) 76 (55–87) 78 (61–89) 71 (50–86) <0.001
Female sex, % 28 25 33 39 26 <0.001
eGFR* 68 (30–103) 80 (62–102) 48 (33–59) 25 (17–30) 12 (9–15) <0.001
ESRD, n 41 3 11 22 5 <0.001
LVEF, % 30 (45–15) 30 (45–15) 30 (45–15) 30 (45–15) 26 (45–11) <0.001
IHD, % 51.9 52.0 49.2 64.0 52.8 <0.001
Diabetes mellitus, % 14.4 21.9 27.1 21.5 7.7 <0.001
Atrial fibrillation, % 23.5 12.6 16.5 23.7 18.9 <0.001
NYHA II+III, % 64.4 61.7 69.3 66.6 72.0 <0.001
Hypertension, % 22.5 23 21 24 28 0.367
Sodium, mmol/L 139 (132–146) 139 (132–146) 139 (132–144) 139 (132–144) 137 (132–145) <0.001
Potassium, mmol/L 4.2 (3.5–4.9) 4.2 (3.5–4.9) 4.3 (3.5–5.1) 4.3 (3.5–5.4) 4.5 (3.3–5.3) <0.001
ACE-I/ARB, % 89.8 92.6 87.8 66.4 60.0 <0.001
ß-Blocker, % 84.0 85.2 82.3 82.0 72.0 <0.001
Aldo Ant, % 30.0 29.8 31.8 21.0 12.0 <0.001
Diuretics,† % 17.7 13.0 23.3 40.4 32.0 <0.001
Statin, % 51.7 51.7 51.8 51.1 36.0 0.015
ASA, % 53.6 53.1 54.1 57.8 44.0 0.250
ACE-I/ARB indicates angiotensin-converting enzyme inhibitor or angiotensin receptor II blocker; Aldo Ant, aldosterone receptor antagonist; ASA, acetylsalicylic acid; 
eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; hypertension, systolic blood pressure >90 mm Hg at baseline; IHD, ischemic heart disease; 
LVEF, left ventricle ejection fraction; and NYHA, New York Heart Association functional class.
*eGFR units: mL/min per 1.73 m2.
†Diuretics; use of >80 mg of furosomide daily or equivalent on daily average.
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being chronic. Diabetic kidney disease (30%) and hypertensive 
and vascular disease (21%) were also dominating. Five percent 
were registered with a primary parenchymal renal disease (ie, 
glomerulonephritis). Ten percent had cancer, polycystic kidney 
disease, or renal infarction.
Discussion
In a large cohort with a long follow-up period, we observed a low 
incidence of ESRD in outpatients with systolic HF. A low eGFR, 
age <60 years, uncontrolled hypertension, and need for diuretics 
were important risk markers for the development of ESRD.
Despite a high proportion of patients in eGFR groups II 
to IV, we observed a low incidence of ESRD. This may be 
explained by several factors, including competing mortality 
risk, contradictions to start of dialysis, and selection bias of the 
cohort, as discussed below.
Mortality rates were 80× higher than ESRD rates and com-
peting risk likely explains the low incidence of ESRD. To 
avoid underestimation of the incidence of ESRD because of 
competing risk, we calculated cumulative incidence function 
and not Kaplan–Meier estimates and observed that the inci-
dence of ESRD could be stratified by eGFR.20 This was also 
the case for the incidence of death.
Selection bias could cause underestimation because it may be 
speculated that patients with systolic HF is not offered dialysis 
in clinical practice because of low systolic blood pressure and 
poor prognosis. It should be noted, however, that HF is not con-
sidered a contraindication to dialysis in Denmark. At baseline, 
25 patients had eGFR <15 mL/min per 1.73 m2 and 5 of those 
started dialysis, based on these small numbers the true incidence 
of ESRD might be ≤5× higher. However, not all patients with 
an eGFR of 15 mL/min per 1.73 require dialysis and it does not 
change the fact that mortality risk is a much larger clinical prob-
lem. It should also be noted that the present cohort consists of 
patients referred to a HF clinic and considered eligible for edu-
cation and uptitration of guideline-recommended therapy. They 
   60–69 0.63 0.57–0.70 <0.001
   ≥80 1.64 1.50–1.80 <0.001
  Uncontrolled hypertension 0.82 0.74–0.91 <0.001
  Diabetes mellitus 1.86 1.07–1.32 0.002
  LVEF <30% 1.24 1.14–1.34 <0.001
  NYHA class III+IV 1.32 1.22–1.44 <0.001
  High-dose diuretics* 1.25 1.19–1.30 <0.001
  ACE-I/ARB 0.54 0.49–0.59 <0.001
  ß-Blocker 0.53 0.49–0.57 <0.001
  Aldosterone antagonist 1.06 0.97–1.16 0.176
  Statin 0.75 0.69–0.82 <0.001
  Acetylsalicylic acid 0.79 0.73–0.86 <0.001
ACE-I/ARB indicates angiotensin-converting enzyme inhibitor or angiotensin 
receptor II blocker; eGFR, estimated glomerular filtration rate; ESRD, end-stage 
renal disease; LVEF, left ventricle ejection fraction; and NYHA Class: New York 
Heart Association functional class.
*Diuretics; use of >80 mg of furosomide or equivalent on average daily.
Table 2. Continued
Hazard 
Ratio
95% Confidence 
Interval P Value
Table 2. Cox Multivariate Proportional Hazard Models: ESRD, 
Mortality Risk, and Composite End Point
Hazard 
Ratio
95% Confidence 
Interval P Value
ESRD: model 0
  eGFR
   Group I (ref) 1.00 . .
   Group II 13.39 3.62–48.6 <0.001
   Group III 322.13 93.3–1112.1 <0.001
   Group IV 1586 365.3–6889.5 <0.001
  Age, y
   ≥70 and <80 (ref) 1.00
   <60 3.07 1.24–7.63 0.016
   60–69 2.89 1.36–6.16 0.057
   ≥80 0.47 0.17–1.34 0.157
  Uncontrolled hypertension 1.9 1.00–3.59 0.049
ESRD: model Ia-c: model  
0 + in separate models:
  Diabetes mellitus 1.83 0.94–3.44 0.073
  ACE-I/ARB 0.54 0.28–1.03 0.061
  High-dose diuretics* 1.39 0.90–1.65 0.023
Mortality risk: model II
  eGFR
   Group I (ref) 1.00
   Group II 1.37 1.26–1.50 <0.001
   Group III 1.83 1.57–2.12 <0.001
   Group IV 2.75 1.72–4.42 <0.001
  Age, y
   ≥70 and <80 (ref) 1.00
   <60 0.35 0.29–0.39 <0.001
   60–69 0.62 0.55–0.69 <0.001
   ≥80 1.67 1.52–1.83 <0.001
  Uncontrolled hypertension 0.81 0.73–0.89 <0.001
  Diabetes mellitus 1.18 1.07–1.32 0.002
  LVEF <30% 1.24 1.15–1.34 <0.001
  NYHA class III+IV 1.32 1.22–1.44 <0.001
  High-dose diuretics* 1.25 1.19–1.30 <0.001
  ACE-I/ARB 0.54 0.49–0.59 <0.001
  ß-Blocker 0.53 0.49–0.57 <0.001
  Aldosterone antagonist 1.07 0.97–1.17 0.166
  Statin 0.75 0.69–0.81 <0.001
  acetylsalicylic acid 0.73 0.73–0.85 <0.001
Composite end point: model III
  eGFR
   Group I (ref) 1.00
   Group II 1.39 1.28–1.52 <0.001
   Group III 1.98 1.71–2.31 <0.001
   Group IV 3.36 2.12–5.34 <0.001
  Age, y
   ≥70 and <80 (ref) 1.00
   <60 0.38 0.30–0.40 <0.001
(Continued )
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represent a selected group, possibly in better clinical condition 
than the total HF population, and this could lead to underesti-
mation of the true ESRD rate for the population.
Previous studies of incidence of ESRD in HF do not exist, 
but our results can be compared with those found in patients 
with vascular disease, hypertension, and diabetes mellitus.21 
Compared with these patients the observed incidence of ESRD 
is a little lower, which may be explained by a higher mortality in 
patients with systolic HF and by the definition of ESRD as start 
of dialysis, a renal transplant, or death in the mentioned study.
We observed a low rate of progression of ESRD in the pres-
ent systolic HF cohort, but our data also underscore that the 
prevalence of patients with systolic HF requiring dialysis is low.
Despite these reservations our, data clearly demonstrate 
that mortality risk is still a much larger problem than ESRD, 
and that progression of CKD to ESRD is rare in outpatients 
with systolic HF.
Young age, uncontrolled hypertension, need for diuretics, 
and eGFR group II, III, and IV were associated with ESRD, 
but diabetes mellitus was not (Table 2). However, one third 
of all patients who started dialysis had a diagnosis of diabetic 
nephropathy. Young age and uncontrolled hypertension were 
also associated with a decreased mortality risk, whereas eGFR 
groups II to IV and diabetes mellitus were associated with an 
increased mortality risk.
Our data indicate that HF clinics should focus on blood 
pressure if it is not well treated after uptitration in neurohor-
monal blockade and monitor eGFR closely because ESRD 
may develop in patients with a good long term-outcome.
Young age was also associated with time to ESRD in a 
recently large published meta-analysis21 and may be explained 
by the lack of competing risk and selection bias for start of 
dialysis. In a study by van Pottelbergh et al22 in older patients, 
where ESRD was defined as development of eGFR <15 mL/min 
per 1.73 m2 and not as dialysis, it was also observed that older 
age was associated with a lower risk for ESRD. Furthermore, 
lower ESRD risk at any given level of eGFR at old age has been 
reported in other patient groups.23,24 The association between 
young age and time to ESRD in the present study is, therefore, 
biologically plausible and may reflect a natural progressive his-
tory of CKD in systolic HF. eGFR groups II, III, and IV were 
all associated with an increased risk of ESRD and death, which 
clearly indicates that eGFR should be used in clinical practice 
as a predictor for both survival and a renal end point.
Finally, despite the application of cumulative incidence 
functions, we cannot exclude that patients with a poor renal 
function who died would have progressed to ESRD because of 
the fact that eGFR is a strong prognostic factor in HF.
We did not observe that renin–angiotensin–aldosterone 
system blockade was reno-protective (Table 2, model I). 
Treatment was associated with an improved outcome (Table 2, 
model II) after adjustment for eGFR group. The lack of reno-
protective effect may be explained by the nonrandomized 
design of our study, by an increased mortality risk in untreated 
patients, a too short follow-up period or a type II error.
However, several attempts to up-titrate the patients with 
CKD should be done in the HF clinics because of the high 
mortality risk of patients with systolic HF and CKD. Because 
of declining tolerance of drugs, according to renal function, 
our data also indicate a potential role for a renal sparring ARA 
and K+-binding polymer in patients with systolic HF and 
CKD, but the potential effect remains to be examined.25,26
A need of diuretics, defined as an average daily dose of >80 
mg of furosomide (or equivalent), was associated with time to 
ESRD independently of eGFR levels. Whether this associa-
tion reflects confounding by indication, for example, patients 
with HF who need high doses of diuretics have impaired renal 
blood flow and increased tubular reabsorption of sodium and 
water, or a true association between doses of diuretics and 
time to ESRD cannot be deduced from our results.
Strengths and Limitations
Some methodological strengths and limitations should be 
discussed. First, the generalizability of our data is limited to 
patients with systolic HF and mild and moderate symptoms 
Table 3.  Crude Rates for the End Points: End-Stage Renal Disease and Death
N ESRD, n ESRD Rate *(95% CI) Death, n Death rate *(95% CI)
All 8204 41 1.3 (0.9–1.7) 2652 84.0 (81.0–87.1)
eGFR
  Group I 5112 3 0.1 (0.0–0.3) 1165 55.4 (52.3–58.5)
  Group II 2695 11 1.2 (0.5–1.8) 1223 129 (122–135)
  Group III 372 22 23.0 (13.5–32.5) 246 244 (217–270)
  Group IV 25 5 106 (18.2–194) 18 340 (212–467)
CI indicates confidence interval; eGFR, estimated glomerular filtration rate; and ESRD, end-stage renal disease.
*Rates: number of events per 1000 patient-years.
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Figure 2. Incidence of end-stage renal disease (ESRD) and 
death. Incidence of end-stage renal disease according to esti-
mated glomerular filtration rate (eGFR)-group and for the entire 
cohort, shown as numbers per 1000 patient-years.
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considered eligible for uptitration in neurohormonal blockade. 
The results should not be extrapolated to patients with acute, 
advanced or terminal HF27 nor to patients with HF with pre-
served EF. It may be speculated that the incidence of ESRD 
is higher in patients with preserved EF because of a better 
long-term outcome and in acute and patients with advanced 
HF because of hemodynamic instability. The majority of 
patients had an eGFR ≥30 mL/min per 1.73 m2 and more data 
on patients with systolic HF who were not considered eli-
gible for uptitration of guideline-recommended therapy with 
an eGFR <30 mL/min per 1.73 m2 are needed. The present 
cohort consists of whites and our results should, therefore, be 
extrapolated to other ethnic and racial groups with caution.
The number of renal end points (n=41) should be noted 
and the lack of association between drug therapy and time to 
ESRD may reflect lack of power.
We have only 1 measurement of serum creatinine concentra-
tion at the baseline visit in HF clinic, and it may be argued that 
it has resulted in misclassification of eGFR. Nor was a follow-
up creatinine available, and short-term deterioration of eGFR 
may have occurred. However, the creatinine was registered in 
outpatients in a stable setting, and eGFR groups behaved as 
expected with respect to prediction of mortality risk and risk of 
ESRD, so misclassification seems not to be an issue. We defined 
ESRD as start of dialysis and not as progression of eGFR to 15 
mL/min per 1.73 m2 and may therefore have underestimated 
the true incidence of ESRD. However, the observed incidence 
seems realistic in relation to the mortality rate, if our data are 
compared with ESRD rates in patients with cardiovascular 
disease and diabetes mellitus, with a lower mortality rate but 
higher ESRD rate, where ESRD was defined as start of dialysis, 
a renal transplant, or death.21 Unmeasured confounding by albu-
minuria, hemoglobin, cardiac and kidney injury markers might 
also have changed our results but were not available.5,28 From 
2002 to 2009, ≈5% to 10% of the patients with systolic HF 
received a cardiac resynchronization device or implantable defi-
brillator in Denmark and it may, therefore, be considered that a 
higher device implantation rate would have improve survival 
even more and thereby increase the risk of ESRD.29 However, 
data comparable with ours from United Kingdom suggest that 
the survival benefit in systolic HF is driven by treatment with 
ACE-I/ARB and β-blockers.9,11 The strengths of our data are the 
long follow-up period of a large number of patients with sys-
tolic HF treated in clinical practice in outpatient HF clinics and 
our possibility to obtain vital status and start of dialysis from 
nationwide registries without any patients lost to follow-up.
Conclusions
During a long period of follow-up we observed a low require-
ment for dialysis in outpatients with systolic HF and despite 
improved survival in systolic HF, mortality risk is still a much 
larger clinical problem than risk of ESRD. eGFR group, 
younger age, need for diuretics, and uncontrolled hyperten-
sion are important risk markers for the development of ESRD.
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CLINICAL PERSPECTIVE
Renal dysfunction is the most frequent comorbidity in systolic heart failure (HF). For years it has been known that renal dys-
function is associated with an increased risk of death and risk of a HF admission. It is also known that therapy that improves 
survival in systolic HF has renal side effects and that monitoring of plasma creatinine and plasma potassium is necessary. 
Despite several publications of the role of the kidneys in HF it is still unknown if the proportion of patients with HF and 
renal dysfunction progress to end-stage renal disease (ESRD) requiring renal replacement therapy. In the present study, we 
investigated whether renal dysfunction progresses to ESRD in a large cohort of outpatients with systolic HF and identified 
predictors for ESRD. We observed that the incidence of ESRD is low and that the risk of death is substantially increased 
on progression. A low estimated glomerular filtration rate, young age, need of diuretics, and hypertension were associated 
with progression to ESRD. Our analyses suggest that despite improved survival in systolic HF, risk of death is still a much 
larger clinical problem than risk of ESRD, and that in patients with stable HF, fear of ESRD in patients with moderate renal 
dysfunction should not discourage uptitration of guideline-based therapy in HF clinics where renal function is closely moni-
tored. Overall, the need of renal replacement therapy in outpatients with systolic HF is low.
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SUPPLEMENTAL MATERIAL 
 
 
 
 Supplemental Table 1: Cox Proportional Hazard Model for ESRD for eGFR II and III 
ESRD: eGFR-group II Hazard Ratio 95 % Confidence Interval P-value 
    
Age ≥70 and <80 (ref) 1.00   
Age <60 1.55 0.17-14.1 0.699 
Age 60-69 1.60 0.39-6.40 0.529 
Age ≥80 0.93 0.17-5.19 0.937 
    
Uncontrolled hypertension 1.47 0.38-5.70 0.574 
Diabetes 1.44 0.36-5.85 0.608 
LVEF <30% 1.15 0.33-4.03 0.828 
NYHA class III+IV 1.49 0.43-5.71 0.533 
    
High doseiuretics* 1.42 0.80-2.46 0.236 
ACE-I/ARB 0.39  0.11-1.40 0.148 
ß-Blocker 0.64 0.16-2.54 0.524 
Aldosterone Antagonist 1.08 0.28-4.21 0.909 
Statin 1.67 0.44-6.32 0.451 
Acetylsalicylic Acid 0.97 0.27-3.46 0.959 
    
ESRD: eGFR-group III Hazard Ratio 95 % Confidence Interval P-value 
    
Age ≥70 and <80 (ref) 1.00   
Age <60 3.78 1.23-12.69 0.031 
Age 60-69 2.53 0.88-7.22 0.090 
Age ≥80 0.13 0.02-1.04 0.054 
    
Uncontrolled hypertension 3.56 1.35-9.42 0.011 
Diabetes 1.56  0.57-4.25 0.385 
LVEF <30% 0.57 0.22-1.45 0.238 
NYHA class III+IV 1.77 0.66-4.72 0.255 
    
High doseiuretics* 1.73  0.78-1.76 0.441 
ACE-I/ARB 0.45 0.17-1.23 0.121 
ß-Blocker 1.13 0.33-3.80 0.849 
Aldosterone Antagonist 0.82 0.23-2.88 0.758 
Statin 2.00 0.70-5.70 0.196 
Acetylsalicylic Acid 0.39 0.15-1.05 0.062 
    
ACE-I/ARB: Angiotensin Converting Enzyme Inhibitor or angiotensin receptor II blocker; CKD: 
Chronic Kidney Disease; ESRD: End-stage Renal Disease; LVEF: Left Ventricle Ejection Fraction; 
NYHA Class: New York Heart Association functional class. *Diuretics; use of more than 80mg 
Furosomid daily on average or equivalent 
 
 Supplemental Table 2:  “Missing creatinine” vs. study population 
Baseline             Study population  Missing creatinine  P-value 
         
N  8204   2239    
Age  70.0   69.0   0.418 
Gender fem.  28 %  29 %  0.434 
         
LVEF <30%  56 %  67 %  <0.001 
IHD  51.9 %  25.4 %  <0.001 
Diabetes   14.8 %  14.6 %  0.779 
NYHA I+II  77.4 %  87.5 %  <0.001 
Uncontrolled hypertension  22.5 %  8.4 %  <0.001 
         
ACE-I/ARB  89.8 %  88.1 %  0.009 
ß-blocker  84.0 %  78.8 %  0.001 
Aldosteron Antagonist  30.0 %  22.6 %  <0.001 
Statin  51.7 %  49.4 %  0.023 
Diuretics*  17.7 %  19.5 %  0.032 
Acetylsalicylic Acid  53.6 %  50.9 %  0.007 
         
Events Study population  (95%CI)  Missing creatinine 95%CI  
         
ESRD (N) 
 
41  
 
15  
  
ESRD rate 
 
1.3 (0.9-1.7) 
 
1.8 (0.9-2.8) 
 
  
Death (N) 
 
2652  
 
709  
  
Death rate 
 
84.0 (81.0-87.1) 
 
86.0 (80.0-92.1) 
 
         
ACE-I/ARB: Angiotensin Converting Enzyme Inhibitor or angiotensin receptor II blocker; CKD: Chronic 
Kidney Disease; ESRD: End Stage Renal Disease; IHD: Ischemic Heart Disease; LVEF: Left Ventricle 
Ejection Fraction; “Missing Creatinine”: Patients excluded from the study population due to missing value of 
creatinine at baseline. NYHA Class: New York Heart Association functional class. Rate: events per 1000 
patient years *Diuretics; use of less than 80mg Furosomid daily on average or equivalent. 
 
